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In case of breast cancer the grade of differentiation and expression of oestrogen
and progesterone receptors falls within the first category of prognostic factors
according to the College of American Pathologists. HER-2, p53 and Ki67 belong
to the second category and their significance still awaits confirmation. The aim of
the present study was to examine the relationship between the intensity of ex-
pression of oestrogen receptors (ER), progesterone receptors (PgR), HER-2, p53
and Ki67 in cells of ductal breast cancer of G1, G2 or G3 differentiation grade. In
paraffin sections of 60 ductal breast cancers (20 cases in G1, 20 in G2 and 20 in
G3), immunocytochemical reactions were performed to detect the expression of
ER, PgR, HER-2, p53 and Ki67. Following a semi-quantitative appraisal of the
preparations under examination, appropriate statistical tests were used to docu-
ment significant relationships. We noted significant positive correlations between
ER and PgR (the entire group studied, G1–3, and the G1 group), HER-2 and p53
(G2) and between p53 and Ki67 expression (G2). Significant negative correlations
were found between ER and p53 (G1–3), PgR and p53 (G1–3, G1, G3) and be-
tween PgR and Ki67 (G1–3, G2). The studies performed demonstrated distinct
relationships between the expression intensity of various proteins in tumour cells
in relation to the grade of differentiation of the tumour. We also showed that
a parallel determination of ER, PgR and p53 expression may carry high predictive
value as to response to tamoxifen treatment.
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INTRODUCTION
Breast cancer is the most common malignant
tumour among females in the western world. The
incidence of breast cancer remains high and clinical
courses are highly variable. It is of general impor-
tance to predict the biology of the tumour and thus
the course of the disease in the individual patient in
order to ensure adequate therapy and patient sur-
10
Folia Morphol., 2005, Vol. 64, No. 1
veillance. In 1999, under the auspices of the College
of American Pathologists, a multi-disciplinary group
of clinicians, pathologists and statisticians examined
prognostic and predictive factors related to breast
cancers and categorised them according to their
value and the number of respective publications [4].
Three categories of prognostic factors were distin-
guished. Factors of the first category carried an es-
tablished clinical value and continue to be used in
daily clinical practice (tumour size, metastases to the
lymph nodes, grade, histological type, mitotic index
and receptors for oestrogen and progesterone). The
second category grouped factors whose significance
required confirmation in subsequent clinical studies
(HER-2, p53, Ki67, PCNA). Factors of the third cate-
gory are at present at the stage of testing and their
prognostic value has not yet been established (DNA
ploidy, neoplastic angiogenesis, EGFR, TGF alpha, Bcl-2,
pS2 and cathepsin D).
Breast cancer grade is appraised on the basis of
its histological structure and the extent of atypia of
the cell nuclei. In cases of an infiltrating ductal can-
cer, grade is established according to the modified
grading of Bloom and Richardson [3]. Studies on the
relationship between the grading of the tumours and
the survival of patients demonstrated an extensive
correlation between the variables, despite the fact that
the data were accumulated by several pathologists
and various scales of evaluation were employed [12].
In around 60% of all breast cancer cases tumour
cells carry oestrogen receptors (ER) and progester-
one receptors (PgR). Around 20% of cases manifest
no receptors for the hormones. The cases demon-
strating expression of both receptors are known to
be the ones to respond most frequently by remis-
sion to treatment with tamoxifen. The presence of
ER by itself has been accepted as an independent
prognostic and predictive factor. As compared to ER,
the significance of PgR expression has proved to be
much less unequivocal [15].
In 1987 Slamon et al. [14] reported that cases of
advanced breast cancer with amplification of the
HER-2/neu gene manifested shorter remission and
shorter survival. Later, overexpression of the HER-2
receptor was also noted as being linked to a less
favourable response to treatment in schemes based
on cyclophosphamide, methotrexate and 5-fluorou-
racil but to a better clinical response to administra-
tion of anthracyclines [9].
The P53 gene was first described in 1979. Its
mutations are detected in approximately one third
of breast cancer cases. Mutations of the P53 gene
extend the half-life of p53 protein. Immunocytochem-
ical detection of overexpression of the protein, there-
fore, is in most cases equivalent to detection of
mutation of the gene. Breast cancer cases with P53
mutation are less differentiated and exhibit a more
aggressive course and shorter survival [5, 10].
Ki67 protein is characteristic for cells in the mi-
totic cycle and represents an unfavourable prognos-
tic index [13]. The intensity of expression of the pro-
tein correlates directly with the grade of tumour dif-
ferentiation [2].
The aim of the present study was to examine the
relationships between the intensity of expression of
oestrogen and progesterone receptors, HER-2, p53
and the intensity of proliferation (Ki67) in cells of
ductal breast cancer of individual grades of differen-
tiation (G1, G2, G3). Such an analysis of relationships
between prognostic factors of the first category with
those of the second category may enable the signifi-
cance of the latter to be defined more precisely.
MATERIAL AND METHODS
Immunocytochemical analysis was performed
retrospectively on tissue samples that were taken for
routine diagnostic purposes. Based on histology (in-
vasive ductal breast cancer) and grade (equal groups
for each grade), 60 patients with primary invasive
breast cancer who were diagnosed in the years 1999
to 2000 in the Lower Silesian Centre of Oncology
(Wroclaw, Poland) were analysed. The mean age of
the patients amounted to 55.62 years ± 9.86 SD
(age range: 43 to 72 years). Each of the grades G1,
G2 and G3 were represented by 20 cases. Samples
isolated from the tumours were fixed in 10% buf-
fered formalin and embedded in paraffin. In all cas-
es haematoxylin and eosin stained preparations were
prepared and subjected to histopathological evalu-
ation, including independent assessment of the
grade by two independent pathologists, according
to a modified version of the Bloom-Richardson scale.
Formalin-fixed paraffin-embedded tissue was
freshly cut (4 µm). The sections were mounted on Su-
perfrost slides (Menzel Glaeser, Germany), dewaxed
with xylene, and gradually rehydrated. The activity of
endogenous peroxidase was blocked by 30-minute
incubation in 1% H2O2. The sections under examina-
tion were boiled for 15 minutes in Target Retrieval
Solution in a microwave oven. Immunocytochemical
reactions were performed using the antibodies to
oestrogen receptor (clone 1D5, optimally prediluted),
progesterone receptor (clone 1A6, optimally predi-
luted), HER-2 (polyclonal antibodies, dilution 1:250),
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p53 (clone DO-7, dilution 1:100) and Ki67 (clone MIB-1,
dilution 1:100). The antibodies were diluted in the
Antibody Diluent, Background Reducing. The sections
tested were incubated with the antibodies for 1 hour
at room temperature. Subsequently, incubations were
performed with biotinylated antibodies (15 minutes
at room temperature) and with streptavidin-biotiny-
lated peroxidase complex (15 minutes at room tem-
perature) (LSAB+, HRP). DAB was used as a chro-
mogen (7 minutes at room temperature). All the sec-
tions were counterstained with Meyer’s haematoxylin.
In each case controls were included in which a specific
antibody was substituted by the Primary Mouse Neg-
ative Control. All the reagents originated from Dako-
Cytomation, Denmark.
The intensity of the immunocytochemical reac-
tions was quantitated by two pathologists using the
following scales:
— in cases of ER and PgR the scales applied took
into account the percentage of cells yielding a pos-
itive reaction (0: negative, 1: < 10%, 2: 10–30%
and 3: >30% of positive cells);
— for evaluation of HER-2 reactivity the DakoCy-
tomation scoring system was used (0: negative;
+ partially membranous; ++ completely mem-
branous, weak; +++ completely membranous,
strong);
— p53 was evaluated using the semi-quantitative
IRS scale, which paid attention to the proportion
of positive cells as well as the intensity of the
reaction. The final result was obtained by multi-
plying the scores given for each of the traits and
the product ranged between 0 and 12 [11];
— expression of Ki67 was quantitated by scoring
cells with a positive reaction.
Statistical analysis of the results obtained was
conducted using Statistica 98 PL software (Statsoft,
Poland). The expression intensities of individual an-
tigens in groups G1, G2 and G3 were compared us-
ing the Kruskal-Wallis ANOVA rank test. Since the
distribution of the ER, PgR, HER-2 and p53 variables
could not be considered normal (as shown by the
Lilliefors test), gamma correlation was employed to
examine relations between individual variables.
RESULTS
The studies performed documented the follow-
ing pattern of immunocytochemical reactions:
— in cases of oestrogen receptor, progesterone re-
ceptor, p53 and Ki67 the colour reaction was loc-
alised in the cell nuclei (Fig. 1–4). The intensity of
the reaction varied in individual cases (Table 1);
Figure 3. Immunocytochemical localisation of p53 expression in
the cells of invasive ductal breast cancer (haematoxylin, ¥ 200).
Figure 2. Immunocytochemical localisation of progesterone re-
ceptor expression in the cells of invasive ductal breast cancer
(haematoxylin, ¥ 200).
Figure 1. Immunocytochemical localisation of oestrogen recep-
tor expression in the cells of invasive ductal breast cancer (hae-
matoxylin, ¥ 200).
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— in the case of the HER-2 receptor the colour reac-
tion showed membrane localisation (Fig. 5). In
this case the intensity of the reaction also varied
between individual cases (Table 1).
Comparison of the expression intensity of the
markers studied between the individual grades of
differentiation demonstrated the following signifi-
cant differences:
— the intensity of PgR expression proved to be the
highest in the G1 group and the lowest in the G3
group of cases (Table 1);
— Ki67 was detected in the lowest fraction of cells
in the G1 group and the highest proportion of
cells in the G3 group (Table 1).
In cases of ER, HER-2 and p53 no significant dif-
ferences were disclosed between groups G1, G2 and
G3 (Table 1).
At the second stage of statistical analysis the
relationships of all the variables were examined in
pairs in patients of all 3 groups taken together (G1,
G2 and G3) and in each group individually (G1, G2
or G3).
In the entire material (groups G1 to G3) signifi-
cant correlations were detected between:
— ER and PgR (positive correlation),
— p53 and Ki67 (positive correlation),
— ER and p53 (negative correlation),
— PgR and Ki67 (negative correlation),
— PgR and p53 (negative correlation).
In the G1 group significant correlations were de-
tected between:
— ER and PgR (positive correlation),
— PgR and p53 (negative correlation).
In the G2 group significant correlations were de-
tected between:
— HER-2 and p53 (positive correlation),
— PgR and Ki67 (negative correlation).
In the G3 group only a negative correlation was
observed between PgR and p53.
In the remaining pairs of variables no correlations
were detected. The results of the analysis are pre-
sented in Table 2.
DISCUSSION
The aim of the study was to analyse the manifes-
tation of receptors for female sex steroids (ER and
Figure 5. Immunocytochemical localisation of HER-2 expres-
sion in the cells of invasive ductal breast cancer (haematoxylin,
¥ 100).
Figure 4. Immunocytochemical localisation of Ki67 expres-
sion in the cells of invasive ductal breast cancer (haematox-
ylin, ¥ 400).
Table 1. Intensity of expression of the antigens studied in
the examined material in relation to grade of differentia-
tion (ANOVA Kruskal-Wallis test)
Antigen Grade Mean ± SD Min Max p
ER G1 2.27±0.66 1 3 0.18
G2 1.57±0.97 0 3
G3 1.6±1.24 0 3
G1–3 1.73±1.02 0 3
PgR G1 2.27±0.66 0 3 0.02
G2 1.52±1.07 0 3
G3 0.95±1.14 0 3
G1–3 1.46±1.15 0 3
HER-2 G1 2.27±0.79 1 3 0.45
G2 1.47±0.88 0 3
G3 1.8±0.86 0 3
G1–3 1.77±0.89 0 3
p53 G1 2.18±1.4 0 6 0.09
G2 3.85±2.57 0 12
G3 4.7±2.77 0 12
G1–3 3.82±2.51 0 12
Ki67 G1 11.91±5.34 5 25 0.0001
G2 34.14±14.62 2 80
G3 51.25±13.75 5 75
G1–3 36.02±18.9 2 80
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PgR), HER-2, p53 and of proliferation-related anti-
gen Ki67, in relation to grade in primary invasive
ductal breast cancers in women. The parameters
studied represented the first or second category of
prognostic factors in breast cancer [4].
In the case of ER no significant differences were
detected in the intensity of expression of the recep-
tor between groups G1, G2 and G3. The result did
not confirm the observations of other authors, who
found a lower intensity of ER expression in less dif-
ferentiated cases [1]. The absence of differences in
ER expression between groups in our material does
not necessarily indicate that the less differentiated
cases, associated with less favourable prognosis, are
equally sensitive to the action of oestrogens or anti-
oestrogen drugs. The possibility exists that in less
differentiated cases ER may fail in its function as
a transcription factor. This might reflect a defect or
the prevailing effect on the cells of signals from re-
ceptors of the HER group.
When differences in PgR expression were exam-
ined between groups G1, G2 and G3, the first group
demonstrated the highest and the last group the
lowest intensity of expression of the receptor. This
observation confirmed the hypothesis advanced in
the discussion of differences in ER expression be-
tween individual groups. In the G3 group, PgR was
noted in the lowest percentage of cells. PgR is known
to represent an oestrogen-dependent protein, ap-
pearing in the cell as a result of interaction between
the oestrogen-ER complex and DNA [17]. The less
pronounced expression of PgR in the G3 group dem-
onstrated that the presence of ER in cancer cells is
not necessarily linked to the preserved activity of the
receptor. Moreover, this work supplies evidence that
a more complete evaluation of the sensitivity of
breast cancer cells to the action of oestrogen and
thus their potential sensitivity to anti-oestrogen treat-
ment requires an evaluation of both receptors for
female sex steroids.
No differences were detected between individu-
al groups in the expression of HER-2 and p53.
In the analysis of Ki67 antigen expression, its in-
tensity proved to be lowest in cells of cancers of the
G1 grade and highest in those of the G3 grade. The
result is consistent with reports of other investiga-
tors [16] and confirms the high value of Ki67 as an
exponent of proliferation.
Analysis of relations between variables within the
entire material (Groups 1 to 3) demonstrated a pos-
itive correlation between ER and PgR and a negative
one between PgR and Ki67. The former correlation
corroborates the corresponding data given in the
literature [6, 7] and may confirm the oestrogen-
-dependent character of PgR. It is surprising that
a negative correlation was detected between the in-
tensity of expression of PgR and Ki67 but no reverse
correlation could have been detected between ER
expression and proliferation intensity measured by
Ki67 expression. This seems to confirm the view cited
above that ER expression does not necessarily indi-
cate a preserved function of the receptor and that
Table 2. Correlations between the intensity of expression
of the antigens studied in the group as a whole (G1–3)
and in the G1, G2 an d G3 groups (Gamma correlation)
Pair of variables Grade Gamma p
studied
ER and PgR G1–3  0.35 0.005
G1  0.93 0.003
G2  0.23 0.33
G3  0.29 0.20
ER and HER-2 G1–3 –0.20 0.28
G1 –0.21 0.28
G2 –0.24 0.25
G3  0.22 0.34
ER and p53 G1–3 –0.28 0.02
G1 –0.19 0.56
G2 –0.24 0.57
G3 –0.16 0.44
ER and Ki67 G1–3 –0.38 0.29
G1 –0.21 0.34
G2 –0.14 0.57
G3 0.26 0.19
PgR and HER-2 G1–3 –0.22 0.94
G1 –0.24 0.32
G2 –0.08 0.64
G3  0.05 0.85
PgR and p53 G1–3 –0.31 0.006
G1 –0.66 0.04
G2 –0.06 0.75
G3 –0.45 0.04
PgR and Ki67 G1–3 –0.31 0.01
G1 –0.02 0.93
G2 –0.41 0.03
G3  0.26 0.23
HER-2 and p53 G1–3  0.31 0.14
G1  0.09 0.65
G2  0.38 0.05
G3  0.12 0.55
HER-2 and Ki67 G1–3  0.21 0.28
G1  0.11 0.60
G2  0.02 0.91
G3 –0.24 0.22
p53 and Ki67 G1–3  0.29 0.01
G1  0.33 0.40
G2  0.23 0.50
G3  0.00 1.00
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PgR may represent an index of the preserved activity
of ER. At this point the problem should be posed in
relation to the ER(–) and PgR(+) cases. Such cases
have been analysed in the past. In 1996, Keshgegian
and Cnaan [8] described studies performed on 300
breast cancer patients, among whom the ER(–) and
PgR(+) cases proved to carry the worst prognosis.
Thus it seems that PgR represents a favourable prog-
nostic and predictive factor only when it is co-ex-
pressed with ER.
In groups G1–3 we also demonstrated a positive
correlation between p53 and Ki67 as well as nega-
tive correlations between p53 on the one hand and
ER and PgR on the other. The information indicates
that cases with P53 mutation exhibit a higher de-
gree of proliferation intensity and a lower degree of
sensitivity to oestrogens and, linked to this, a lower
degree of sensitivity to tamoxifen treatment [15].
Studies on the relationships between variables in
the G1 group detected a positive correlation between
ER and PgR and a negative correlation between PgR
and p53. In the G2 group a positive correlation was
detected between HER-2 and p53 and a negative
correlation between PgR and Ki67. In the G3 group
we detected a negative correlation between PgR and
p53. The results corroborate the data obtained for
the entire material (groups G1 to G3). PgR expres-
sion has been found to be negatively related to pro-
liferation intensity and has demonstrated a relation
to ER. The negative correlation between PgR and p53
expression, detected in all groups except G2, deserves
attention. The absence of a relationship between the
expression of PgR and p53 in the G2 group may have
reflected a decrease in PgR expression and a parallel
increase in p53 expression in the course of transi-
tion of the tumour from G1 to G3. The intensity of
HER-2 expression was higher in cases with mutation
of the p53 gene.
The studies performed indicate that the value of
individual markers and relations between individual
variables vary depending upon the grade of differ-
entiation of cancerous cells. The conclusion can be
drawn that the value and function of the individual
proteins tested can be recognised only after exam-
ining them in various groups of tumours. As a start-
ing point, the parameters analysed should include
the grade of tumour differentiation, tumour size, the
presence of metastases and histological type. If in
our studies expression of ER, PgR, HER-2, p53 and
Ki67 had been examined in only one of the groups,
the results obtained would have been different. It is
worth noting that we have disclosed most of the
relations in the entire group studied (consisting of
an identical number of cases of each of the individ-
ual grades of differentiation) and the least frequent
relations have been observed in the G3 group with
cases of low differentiation. The extensive differenc-
es between the results of various authors probably
reflect groups for study that were too narrow or in-
appropriately selected.
The present study indicates that the value of ER
as an independent prognostic and predictive factor
can depend upon the grade of tumour differentia-
tion. The study also indicates that a parallel evalua-
tion of ER, PgR and p53 expression may prove to be
of high predictive value in prognosis concerning re-
sponse to tamoxifen treatment.
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